Introduction
Many Western countries are experiencing an epidemic of renal calculi, causing immediate problems with acute pain and morbidity together with worries for the future because of the likelihood of recurrent stone formation. Renal or ureteric colic is the commonest surgical admission diagnosis in this country and it has been suggested that up to 12 million Americans will suffer a stone episode during their lifetime.' Because of the scale of the clinical problem presented by renal colic, immediate and short-term management dominates the discussion with rather less attention paid to analysis of the factors involved in stone formation and prevention of recurrence. In view of the substantial costs of the treatment of kidney stones ($2 billion in 1986 in the USA alone2), this focus may not be altogether appropriate.
Most upper tract stones are composed ofcalcium oxalate and the definition of 'idiopathic hypercalciuria' some 60 years ago has tended to emphasize the importance of increased urinary calcium excretion in their aetiology. However, in the last 10-15 years, it has become clear that quite small changes in urinary oxalate levels may have profound effects on the likelihood of calcium oxalate crystal formation and subsequent urolithiasis.3 The current interest in hyperoxaluria and its pathophysiology results from the development of accurate methods of measuring oxalate in blood and urine4'5 and advances in our understanding of the physical processes involved in urinary crystal formation. 6 We review some current thinking on oxalate and renal calculi; a number of excellent recent reviews on the broader aspects of urolithiasis are also available.' [7] [8] [9] Biochemistry of oxalate Oxalic acid is a strong dicarboxylic acid present as oxalate in plasma at 1-3 jtmol/l and excreted in the urine at about 0.2-0.4 mmol/24 h. The solubility of oxalate in water is only about 50 pmol/l so that the importance of naturally occurring inhibitors of crystallization in urine, such as citrate and nephrocalcin, is obvious. A typical diet contains 1-2 mmol oxalate per day, of which more than 95% is precipitated in the gut lumen and excreted in the form of insoluble calcium salts. Thus the absorption of oxalate from the gut lumen may depend on the adequacy of the dietary intake of calcium.'0 Most urinary oxalate is derived from endogenous metabolism, although heavy consumption of oxalate rich foods such as nuts, chocolate, tea or spinach can introduce an important dietary component to hyperoxaluria, but this is unusual. The metabolism of glyoxylate and glycine gives rise to oxalate, with lesser amounts coming from hydroxyproline, other amino acids and sugars. Although ascorbic acid is also a precursor it seems that this route is fairly limited, because the consumption ofmega doses of vitamin C (5-10 g per day) causes only mild hyperoxaluria.
Oxalate is a metabolic end product, the excretion of which is made entirely via the urine, apart from some possible intestinal excretion of trivial degree. It is not significantly protein bound so that it is freely filtered at the glomerulus; additional secretion occurs in the tubule so that, in normal individuals, oxalate clearance may be 50-100% greater than that of creatinine."1 Sixty per cent of urinary oxalate forms a soluble complex with sodium with the remainder forming a variety ofless soluble calcium complexes.
Factors in crystal fonnation
Normal urine is supersaturated with respect to many of its constituents such as oxalate, calcium, urate, phosphate, etc. All urine contains a variety It is common to find hypocitraturia in patients with calcium oxalate calculi, although this requires a specialist laboratory; urine citrate varies with pH and the normal ranges for men and women are very different. Citrate is the most important inhibitor of calcium oxalate crystal formation in normal urine because it forms soluble complexes with free calcium oxalate crystal formation in normal urine because it forms soluble complexes with free calcium ions."' Low urine citrate levels are associated, for example, with a high animal protein intake, thiazide-induced hypokalaemia and volume depletion and can be increased by oral alkali supplements. Oral potassium citrate is widely used in the USA, and has been shown to reduce the likelihood of stone growth and recurrence.
Alkali administration, as well as increasing urinary citrate, will also correct the very acid urine (pH less than 5.5) found in about 25% of stone formers. An acid urine will tend to promote uric acid crystallization that can act as a nidus for calcium oxalate crystals (epitaxy) and also bind macromolecular inhibitors.6 Low urine pH may be associated with relative oliguria or chronic diarrhoea, and will aggravate the risks of crystallization associated with the hyperuricosuria that is present in about 20% of patients with calcium oxalate stones.
Causes of hyperoxaluria A complete list of the possible causes of hyperoxaluria is given in Table I , although only those 
Mild metabolic hyperoxaluria
About 20% of patients with calcium oxalate calculi are found to have mild hyperoxaluria, with urine values of 0.4-0.6 mmol per day. The reason for this is unclear, although occasionally a dietary component can be identified and corrected. Urinary glycollate levels are normal so that a mild variant of PH l can be excluded. It seems likely that some patients do have truly enhanced endogenous oxalate production or increased absorption of dietary oxalate,'9 combined in some cases with reduced urinary clearance so that plasma oxalate levels may be elevated. These patients tend to have normal urinary levels of calcium and citrate, although hyperuricosuria may be associated. Typically, the response to pyridoxine supplementation is either absent or short-lived and the exact biochemical abnormality in these patients has yet to be defined. urine and low levels of urinary inhibitors. Management of enteric hyperoxaluria may be very difficult and involves increasing the luminal calcium concentration with supplements of calcium carbonate, dietary restriction of fat and oxalate together with treatment, if possible, of the underlying cause.2'
Conclusion
In this country, at least, the metabolic investigation of patients with recurrent renal calculi has not attracted the attention it deserves. This is partly because of the improved techniques for stone removal, such as lithotripsy and percutaneous nephrolitotomy and partly because of the immense clinical load represented by this group of patients. A comprehensive metabolic screen (Table II) in stone-forming patients involves a variety of relatively simple tests on blood and urine that should be within the scope of all hospital laboratories. The experience is that, when these tests are done, one or more abnormalities will be detected that are amenable to various therapeutic measures, with a greatly reduced risk of recurrent stone formation. It is likely that the role of oxalate in calcium stone formation will be recognized to be of increasing importance now that accurate methods of measurement have become available. 
